MediciNova, Inc.
Notice Regarding Top-line Results of the Phase 2 Clinical Trial (MN-001-NATG-202) of MN-001 (Taipercast) for Hypertriglyceridemia and Fatty Liver Disease Associated with Type 2 Diabetes
Top-line Phase 2 results of MN-001 (Taipercast) showed a significant reduction in TG, significant increases in HDL-C and HDL-P, and trends toward improvement in liver fat content and body weight. Safety was favorable. Further large-scale trials to evaluate efficacy will continue. No impact on consolidated results for the fiscal year ending December 2026.
Key Figures
- Difference in TG reduction at 4 weeks: 30.96 mg/dL
- Difference in HDL-C increase at 24 weeks: 5.7 mg/dL (p=0.0048)
- Difference in HDL-P increase at 24 weeks: 4.52 µmol/L (p=0.018)
AI要約
Study Overview and Key Results
This was a multicenter, randomized, double-blind, placebo-controlled proof-of-concept trial in which 40 subjects received MN-001 (500 mg/day) or placebo for 24 weeks. The trial demonstrated an early reduction in TG, significant increases in HDL-C and HDL-P, and trends toward improvement in liver fat content and body weight, while the TG reduction difference at 24 weeks was not statistically significant. Safety was generally favorable.
Outlook and Impact
This trial was an exploratory POC study; going forward, efficacy will be evaluated in larger clinical trials. The company will continue to consider appropriate patient populations, endpoints, and sample sizes for the next phase. It is explicitly stated there is no impact on consolidated results for the fiscal year ending December 2026.
MediciNova, Inc.
Company overview · Stock price · Financial data · All IR
